We observed a high TFR rate in children with CML‐CP in our cohort, the modified and less frequent BCR::ABL1 transcript monitoring strategy after imatinib cessation was found to be pragmatic and reasonably safe. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.